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members to choose either retail or mail pharmacy as their preferred distribution 
channel. METHODS: Claims (n  168,381) submitted between Apri, 1, 2008 and 
December 31, 2008 for an employer after it began offering the same price on 90-day 
retail and mail maintenance prescriptions were used to calculate Medication Posses-
sion Ratio (MPR), Generic Dispensing Rate (GDR), Generic Substitution Rate (GSR), 
and Preferred Brand Dispensing (PBDR) for patients impacted by the beneﬁ t. GDR, 
GSR, and PBDR were calculated for all claims with a 90-day supply. MPR was cal-
culated for all patients who were eligible 180 days before and after their ﬁ rst 90-day 
prescription between April 1 and June 30, 2008 for each maintenance class, using that 
ﬁ rst prescription and any within the subsequent 180 days. Overall metrics and those
for select classes with sufﬁ cient sample size are presented. RESULTS: The average 
MPR, across all classes, was 80% for retail dispensed prescriptions and 78% for mail. 
Among six high-volume classes, the average MPR was 82% at retail and 81% at mail,
with MPRs for individual classes ranging from 75% (PPIs) to 89% (ACEs and Anti-
convulsants) for retail-dispensed and 74% (SSRIs) to 85% (ACEs) for mail-dispensed. 
When comparing retail and mail dispensed prescriptions, GDR (57% vs. 56%), GSR
(99% vs. 99%), and PBDR (86% vs. 86%) were nearly identical. CONCLUSIONS:
When out-of-pocket costs and days supply per prescription are identical, adherence 
rates and related formulary performance metrics for mail and retail-dispensed main-
tenance medications appear essentially similar in early results. These pilot results will
need to be conﬁ rmed as more payers adopt this beneﬁ t design and longer follow-up
periods improve adherence measurement precision.
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OBJECTIVES: The literature was reviewed to determine the impact of Medicare sup-
plement insurance (i.e. Medigap) on the Medicare program with respect to access, 
utilization, outcomes, costs, and drug compliance. Additionally, we discuss a new
program to improve pharmaceutical utilization for Medigap enrollees. METHODS:
We conducted a literature search using PubMed, looking for peer-reviewed articles
that compared access, utilization, outcomes and costs between enrollees with Medicare
fee-for-service coverage alone to those with Medigap. Additional searches focused on
differences in pharmacological compliance, for those with and without drug coverage, 
among the two groups. Finally, we searched for pharmacy compliance programs 
offered through supplement insurance plans. RESULTS: Twenty-seven articles met our 
search criteria. The literature suggests Medicare Supplement Insurance can be cost-
effective, that it is correlated with better access to health care services, and may result 
in higher utilization of preventive services than would be the case without such cover-
age. Also, the type of supplement insurance did not signiﬁ cantly inﬂ uence prescription 
drugs utilization among Medicare enrollees. No articles found discussed any current
efforts to manage the pharmaceutical treatment of Medicare Supplement Insurance 
enrollees. CONCLUSIONS: Medigap programs have not historically managed their
enrollees like Medicare Advantage plans have done. In particular, the literature sug-
gests there is much room for improvement in pharmacy management for all Medicare
populations, including those enrolled in Medigap plans. This has led AARP and 
UnitedHealth Group to offer a pharmacological compliance program, with disease
management and case management programs, for their AARP Medicare Supplement
Insurance enrollees, beginning in 2009. Results from this care management effort will
help tailor models for more ways to better manage the care for fee-for-service Medicare
enrollees with supplement coverage.
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OBJECTIVES: To compare medication possession ratio (MPR), medication persis-
tence & pill wastage in 90-day versus 30-day reﬁ ll channel among 5 different drug
classes. METHODS: We conducted a retrospective study using pharmacy claim data-
base. The cohorts were classiﬁ ed based on the type of reﬁ ll duration (30-day or 90-
day). Patients included in the study were continuously eligible in the insurance plan
for the study duration and were new to therapy during the identiﬁ cation period
(January 1, 2006 to June 30, 2006) and were followed for 21 months after their index 
date. Claims in the ﬁ rst 3-months after the index date were excluded from the analysis 
to avoid immortality bias. Outcomes included MPR, persistence to therapy, and pill
wastage. Pill wastage was calculated only among those who switched therapy within
a pharmacological class of drugs (i.e. diuretics). Therapeutic drug classes included in
the study were antihypertensives (AH), anti-depressants (AD), antihyperlipidemics 
(AL), anti-asthmatics (AA) and anti-diabetics (AD). RESULTS: A total of 8403, 6296, 
7197, 5383 and 2722 subjects in AH, AD, AL, AA and AD drug classes were included. 
MPR and persistency were consistently and statistically higher in the 90-day versus 
the 30-day group at 9-months and 18-months post index among all the 5 drug classes 
studied. There was a consistent trend of decrease in MPR and persistency at 18-months 
in comparison to 9-months follow up in all the 5 therapeutic drug classes studied. The 
higher trend in pill wastage in the 90-day versus 30-day reﬁ ll channel was not consis-
tent across all therapeutic categories. CONCLUSIONS: Members who reﬁ lled 90-day
versus 30-day were associated with a signiﬁ cant higher MPRs and persistency. Efforts
to increase medication adherence should be continued steadily along the course of 
therapy as a medication adherence with chronic medications continues to decrease
over time.
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OBJECTIVES: To describe the patterns of medication discontinuation in a retiree
population. Premature discontinuation of medications adversely affects patients’ out-
comes and may require use of additional health care resources. METHODS: The study
included pharmacy claims from a retirement system for the period January 2000-
September 2005. The unit of analysis was the course of drug therapy (CDT), represent-
ing a unique combination of a patient and a drug product (i.e. generic name, 
formulation and strength). CDTs initiated between August 1, 2000 and July 31, 2001 
and discontinued before March 1, 2005 were included in the analysis. Days in therapy 
for each CDT were calculated as the difference between the date of the ﬁ rst and last 
prescription of the CDT. RESULTS: The study included 1.1 million CDTs representing 
5.9 million claims. 37.0% of CDTs were discontinued with less than a month in
therapy, 50.0% with less than 6 months, and 76.0% within one year. Maintenance
therapy comprised 740,788 CDTs (70.30%) of which 27.0% had a single claim. 
Maintenance therapies had the following cumulative utilization patterns: 36.7% CDTs 
discontinued in less than 3 months of therapy, 45.0% in less than 6 months, 74.7% 
within one year, and 87.2% within two years. 21.6% of non-maintenance CDTs were 
continued for more than a year and 11.8% for more than 2 years. CONCLUSIONS:
Premature discontinuation of therapy intended for long-term use is highly prevalent
with more than one-fourth of all maintenance therapies discontinued at the ﬁ rst pre-
scription, and nearly three-fourths discontinued within the ﬁ st year of therapy. In the
other hand, over one-ﬁ fth of non-maintenance therapies were used for over a year.
The assessment of compliance using claims data should account for discontinuation 
of therapy prior to the potential manifestation of positive patient outcomes and for
the short-term usage of maintenance therapies and prolonged use of non-maintenance
therapies.
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OBJECTIVES: To systematically evaluate studies assessing the outcomes and eco-
nomic value of decreased medication dosing frequency. METHODS: We searched the 
literature from 1998 to 2008 using the MEDLINE database for articles that evaluated 
the cost-effectiveness of dosing frequency changes and adherence. Only non-English 
articles were initially excluded; from the identiﬁ ed citations, all abstracts were
reviewed; those lacking a clear link between dosing frequency changes, adherence, and 
costs or cost-effectiveness analysis (CEA) were excluded. The selected articles were 
thoroughly reviewed and summarized. RESULTS: A total of 168 citations were identi-
ﬁ ed: after exclusions by reviewing the abstracts, 21 were selected and reviewed–18
original studies and three systematic reviews. The articles encompassed several chronic
pathologies, e.g., osteoporosis (seven) and hepatitis C (two). Seven of the ten economic
studies utilized decision modeling frameworks (usually one-year horizon), where the
effect of dosing frequency changes on adherence was not the primary outcome. In 
most cases, assumptions on adherence changes were used as part of the sensitivity
analysis, but lacked support from strong evidence. Only two randomized clinical trials 
where adherence was not the primary outcome reported the effect of dosing changes, 
but focused, as did cross-sectional surveys, on patient preferences instead of cost-
effectiveness. Observational studies and retrospective claims database reviews used
different measures, deﬁ nitions, and methodologies, making it difﬁ cult to summarize
their results. Overall, the studies suggested that less frequent dosing leads to improved 
outcomes, although direct evidence of economic beneﬁ t was often lacking. CONCLU-
SIONS: Due to the lack of direct evidence, head-to-head direct comparisons of dosing 
regimens and long-term prospective studies are ideally needed to evaluate the cost-
effectiveness of less frequent dosing that may improve outcomes through improved
adherence or improved pharmacokinetic/pharmacodynamic effects.
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OBJECTIVES: The aim of this study was to translate and validate a Brazilian version
of the “Prolapse – Quality Of Life Questionnaire” (P-QOL) as a speciﬁ c instrument 
to assess the severity of symptoms and their impact in the quality of life of Brazilian 
women with genital prolapse. METHODS: Sixty-ﬁ ve patients (45 with symptomatic
and 20 with asymptomatic pelvic organ prolapse), were enrolled from the outpatient 
clinic of the Uroginecology and Vaginal Surgery Section of the Gynecology Department
of the Federal University of São Paulo (UNIFESP). At ﬁ rst, we translated the P-QOL 
